Ono Pharmaceutical Co. Ltd
PharmaOsaka, Japan, Japan · Est. 1717 · 12,000 employees
Ono Pharmaceutical is a Japanese pharmaceutical company focused on developing and commercializing innovative medicines in oncology, immunology, and other therapeutic areas.
14
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
20
Indications↗
Distinct diseases across all programs
124
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
14 drugs in development
Phase 33
Phase 26
Phase 111
Preclinical1
By Therapeutic Area
top 3
Oncology
1063%
Neurology
213%
Psychiatry
16%
R&D Momentum
69/100
Pipeline Velocity
37/100
Trial Completion Rate
90/100
Pipeline Concentration
45/100
Pipeline Freshness
73/100
Strategic Signals
- ↗Active in Neurology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Sep 10, 2026
Recruiting
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ONO-6414 Administered Orally as Single Ascending Doses With a Food-Effect Arm and Multiple Ascending Doses in Healthy Adult Participants, and as a Single Dose (Open-Label) in Patients With Active Ulcerative Colitis
Sep 9, 2026
Recruiting
A Multicenter, Open-label, Uncontrolled Phase I/II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma, and to Evaluate the Tolerability in Pediatric Patients.
Sep 9, 2026
Recruiting
A Phase 3 Randomized, Double-blind, Placebo-controlled Global Study of Sapablursen in Polycythemia Vera
Earlier
Sep 5, 2026TrialPhase 1 Dose Escalating and Expansion Study of ONO-4578 Given as Monotherapy and Combinations of ONO-4578 and ONO-4538 in Subjects With Advanced or Metastatic Solid Tumors
Sep 4, 2026TrialA Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants With Relapsed/Refractory Primary Central Nervous System Lymphoma
Sep 1, 2026TrialA Phase II, 26-week, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of ONO-2020 in Patients With Mild to Moderate Alzheimer's Disease
Aug 27, 2026TrialA Phase 1, Open-label, Dose Escalation Study to Investigate the Safety and Tolerability of ONO-7429 in Participants With Unresectable Advanced or Recurrent Solid Tumors
Aug 6, 2026TrialA Phase I, Open-label, Dose Escalation Study to Evaluate the Tolerability and Safety of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors
Details
Company Info
Company Overview
$8.5B
Mkt Cap
$4.5B
Revenue
—
Cash
CEOGenta Nakamura
Founded1717
Employees12,000
HQOsaka, Japan, Japan
Websiteono.co.jp/en/
LinkedInCompany Page
Therapeutic Focus
OncologyImmunologyCardiovascular
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Neurology(2 drugs)
—
—
2
1
—
Neurology(2 drugs)
Oncology(10 drugs)
1
9
4
2
—
Oncology(10 drugs)
Psychiatry(1 drug)
—
—
1
—
—
Psychiatry(1 drug)
Unknown / Other(3 drugs)
—
2
1
—
—
Unknown / Other(3 drugs)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)